How suitable are JAK inhibitors in treating the inflammatory component in patients with alopecia areata and vitiligo?

Click to increase image sizeClick to decrease image size

Disclosure statement

S Feldman has received research, speaking and/or consulting support from a variety of companies including Galderma, GSK/Stiefel, Almirall, Leo Pharma, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Valeant, Abbvie, Samsung, Janssen, Lilly, Menlo, Merck, Novartis, Regeneron, Sanofi, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate and National Psoriasis Foundation. He is founder and majority owner of www.DrScore.com and founder and part owner of Causa Research, a company dedicated to enhancing patients’ adherence to treatment. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Peer review

One peer reviewer was on advisory boards for all three of the oral JAK inhibitors but had no financial stake in any of them or their parent companies. They are on the speaker’s bureau for several companies including the makers of both oral and topical JAK inhibitors, as well as dupilumab. Peer reviewers in this manuscript have no other relevant financial relationships or otherwise to disclose.